tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Paul Matteis, 351 are a BUY (73.28%), 128 are a HOLD (26.72%).
Analyst Paul Matteis, currently employed at STIFEL, carries an average stock price target met ratio of 52.19% that have a potential upside of 44.91% achieved within 227 days.
Paul Matteis’s has documented 931 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Basic Materials, Consumer Defensive sectors.
Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 31-Jul-2026.
Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 3/8/2021. The price target of $27 was fulfilled within 1 day with a profit of $18.78 (41.02%) receiving and performance score of 410.22.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Dec-2025
$33
$13.05 (65.41%)
$37
9 days ago
(25-Sep-2026)
0/3 (0%)
$12.32 (59.57%)
Buy Since 17-Apr-2025
$34
$14.05 (70.43%)
$36
9 days ago
(25-Sep-2026)
4/6 (66.67%)
$13.32 (64.41%)
144
Buy Since 25-Sep-2025
$31
$11.05 (55.39%)
$38
9 days ago
(25-Sep-2026)
2/6 (33.33%)
$10.32 (49.90%)
574
Buy Since 26-Nov-2019
$33
$13.05 (65.41%)
$36
9 days ago
(25-Sep-2026)
9/25 (36%)
$12.32 (59.57%)
238
Buy Since 28-Feb-2024
$35
$15.05 (75.44%)
$41
9 days ago
(25-Sep-2026)
9/15 (60%)
$14.32 (69.25%)
393
Which stock is Paul Matteis most bullish on?
Which stock is Paul Matteis most reserved on?
What Year was the first public recommendation made by Paul Matteis?
